Pivotal role of choline metabolites in remyelination

Brain

Volumn 138, Issue 2, 2015, Pages 398-413

  Skripuletz, Thomas ^a   Manzel, Arndt ^b,c   Gropengießer, Karoline ^a   Schäfer, Nora ^a   Gudi, Viktoria ^a   Singh, Vikramjeet ^a,d   Tejedor, Laura Salinas ^a,d   Jörg, Stefanie ^c   Hammer, Anna ^c   Voss, Elke ^a   Vulinovic, Franca ^a   Degen, Diane ^a   Wolf, Rebecca ^c   Lee, De Hyung ^c   Pul, Refik ^a   Moharregh Khiabani, Darius ^a   Baumgärtner, Wolfgang ^d,e   Gold, Ralf ^f   Linker, Ralf A ^c   Stangel, Martin ^a,d  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d Centre for Systems Neuroscience   (Germany)

^e UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^f ST JOSEF HOSPITAL   (Germany)

Author keywords

Demyelination; EAE; Neuroinflammation; Oligodendrocyte; Remyelination

Indexed keywords

CITICOLINE; CUPRIZONE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PROTEIN KINASE C; CHELATING AGENT; CHOLINE; NOOTROPIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DEMYELINATION; DISEASE COURSE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; IN VITRO STUDY; MOTOR COORDINATION; MOUSE; MOUSE MODEL; MUSCLE REGENERATION; MYELINATED NERVE; NERVE FIBER; NEUROPROTECTION; NONHUMAN; OLIGODENDROCYTE PRECURSOR CELL; OLIGODENDROGLIA; PRIORITY JOURNAL; REMYELINIZATION; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DEMYELINATING DISEASE; DRUG EFFECTS; GLIA; METABOLISM; MYELIN SHEATH; NEURAL STEM CELL; RAT; SPRAGUE DAWLEY RAT; T LYMPHOCYTE;

ANIMALS; CELL PROLIFERATION; CHELATING AGENTS; CHOLINE; CUPRIZONE; CYTIDINE DIPHOSPHATE CHOLINE; DEMYELINATING DISEASES; MICE; MICE, INBRED C57BL; MYELIN SHEATH; NEURAL STEM CELLS; NEUROGLIA; NOOTROPIC AGENTS; OLIGODENDROGLIA; RATS; RATS, SPRAGUE-DAWLEY; T-LYMPHOCYTES;

EID: 84922345039     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awu358     Document Type: Article

References (50)

1. Adibhatla RM, Hatcher JF. Cytidine 50-diphosphocholine (CDP-choline) in stroke and other CNS disorders. Neurochem Res 2005; 30: 15-23.
2. Adibhatla RM, Hatcher JF, Larsen EC, Chen X, Sun D, Tsao FH. CDP-choline significantly restores phosphatidylcholine levels by differentially affecting phospholipase A2 and CTP: phosphocholine cytidylyltransferase after stroke. J Biol Chem 2006; 281: 6718-25.
3. Aktas O, Kieseier B, Hartung HP. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci 2010; 33: 140-52.
4. de Castro F, Bribian A, Ortega MC. Regulation of oligodendrocyte precursor migration during development, in adulthood and in pathology. Cell Mol Life Sci 2013; 70: 4355-68.
5. Clement JM, Kent C. CTP:phosphocholine cytidylyltransferase: insights into regulatory mechanisms and novel functions. Biochem Biophys Res Commun 1999; 257: 643-50.
6. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372: 1502-17.
7. Conant R, Schauss AG. Therapeutic applications of citicoline for stroke and cognitive dysfunction in the elderly: a review of the literature. Altern Med Rev 2004; 9: 17-31.
8. Crowther JR. ELISA. Theory and practice. Methods Mol Biol 1995; 42: 1-218.
9. Davalos A, Alvarez-Sabin J, Castillo J, Diez-Tejedor E, Ferro J, Martinez-Vila E, et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet 2012; 380: 349-57.
10. Davalos A, Secades J. Citicoline preclinical and clinical update 2009-2010. Stroke 2011; 42: S36-9.
11. de Oliveira AC, Candelario-Jalil E, Bhatia HS, Lieb K, Hull M, Fiebich BL. Regulation of prostaglandin E2 synthase expression in activated primary rat microglia: evidence for uncoupled regulation of mPGES-1 and COX-2. Glia 2008; 56: 844-55.
12. Eugster HP, Frei K, Bachmann R, Bluethmann H, Lassmann H, Fontana A. Severity of symptoms and demyelination in MOGinduced EAE depends on TNFR1. Eur J Immunol 1999; 29: 626-32.
13. Franklin RJ, ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci 2008; 9: 839-55.
14. Fukami K, Inanobe S, Kanemaru K, Nakamura Y. Phospholipase C is a key enzyme regulating intracellular calcium and modulating the phosphoinositide balance. Prog Lipid Res 2010; 49: 429-37.
15. Garcia-Cobos R, Frank-Garcia A, Gutierrez-Fernandez M, Diez-Tejedor E. Citicoline, use in cognitive decline: vascular and degenerative. J Neurol Sci 2010; 299: 188-92.
16. Gudi V, Gingele S, Skripuletz T, Stangel M. Glial response during cuprizone-induced de-and remyelination in the CNS: lessons learned. Front Cell Neurosci 2014; 8: 73.
17. Gudi V, Skuljec J, Yildiz O, Frichert K, Skripuletz T, Moharregh-Khiabani D, et al. Spatial and temporal profiles of growth factor expression during CNS demyelination reveal the dynamics of repair priming. PLoS One 2011; 6: e22623.
18. Gutierrez-Fernandez M, Rodriguez-Frutos B, Fuentes B, Vallejo-Cremades T, Alvarez-Grech J, Exposito-Alcaide M, et al. CDP-choline treatment induces brain plasticity markers expression in experimental animal stroke. Neurochem Int 2012; 60: 310-17.
19. Hagemeier K, Bruck W, Kuhlmann T. Multiple sclerosis-remyelination failure as a cause of disease progression. Histol Histopathol 2012; 27: 277-87.
20. Herrero-Herranz E, Pardo LA, Gold R, Linker RA. Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neurobiol Dis 2008; 30: 162-73.
21. Hjelmstad RH, Bell RM. Molecular insights into enzymes of membrane bilayer assembly. Biochemistry 1991; 30: 1731-40.
22. Hunt AN, Clark GT, Attard GS, Postle AD. Highly saturated endonuclear phosphatidylcholine is synthesized in situ and colocated with CDP-choline pathway enzymes. J Biol Chem 2001; 276: 8492-9.
23. Hurtado O, Lizasoain I, Moro MA. Neuroprotection and recovery: recent data at the bench on citicoline. Stroke 2011; 42: S33-5.
24. Kent C, Carman GM. Interactions among pathways for phosphatidylcholine metabolism, CTP synthesis and secretion through the Golgi apparatus. Trends Biochem Sci 1999; 24: 146-50.
25. Kipp M, Clarner T, Dang J, Copray S, Beyer C. The cuprizone animal model: new insights into an old story. Acta Neuropathol 2009; 118: 723-36.
26. Kleinewietfeld M, Manzel A, Titze J, Kvakan H, Yosef N, Linker RA, et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature 2013; 496: 518-22.
27. Kotsiari A, Voss EV, Pul R, Skripuletz T, Ragancokova D, Trebst C, et al. Interferon-beta treatment normalises the inhibitory effect of serum from multiple sclerosis patients on oligodendrocyte progenitor proliferation. Neurosci Lett 2010; 485: 107-11.
28. Kotter MR, Stadelmann C, Hartung HP. Enhancing remyelination in disease-can we wrap it up. Brain 2011; 134: 1882-900.
29. Linker RA, Lee DH, Demir S, Wiese S, Kruse N, Siglienti I, et al. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Brain 2010; 133: 2248-63.
30. Linker RA, Lee DH, Ryan S, van Dam M, Conrad R, Bista P, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011; 134: 678-92.
31. Linker RA, Maurer M, Gaupp S, Martini R, Holtmann B, Giess R, et al. CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med 2002; 8: 620-4.
32. Maier K, Merkler D, Gerber J, Taheri N, Kuhnert AV, Williams SK, et al. Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation. Neurobiol Dis 2007; 25: 514-25.
33. McMaster CR, Bell RM. Phosphatidylcholine biosynthesis via the CDP-choline pathway in Saccharomyces cerevisiae. Multiple mechanisms of regulation. J Biol Chem 1994; 269: 14776-83.
34. Medina-Rodriguez EM, Arenzana FJ, Pastor J, Redondo M, Palomo V, García de Sola R, et al. Inhibition of endogenous phosphodiesterase 7 promotes oligodendrocyte precursor differentiation and survival. Cell Mol Life Sci 2013; 70: 3449-62.
35. Meuth SG, Bittner S, Ulzheimer JC, Kleinschnitz C, Kieseier BC, Wiendl H. Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of neuroprotective and alternative treatment strategies. BioDrugs 2010; 24: 317-30.
36. Mi S, Miller RH, Lee X, Scott ML, Shulag-Morskaya S, Shao Z, et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci 2005; 8: 745-51.
37. Mi S, Miller RH, Tang W, Lee X, Hu B, Wu W, et al. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann Neurol 2009; 65: 304-15.
38. Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel JP. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 2008; 63: 61-71.
39. Muccioli M, Pate M, Omosebi O, Benencia F. Generation and labeling of murine bone marrow-derived dendritic cells with Qdot nanocrystals for tracking studies. J Vis Exp 2011.
40. Mykita S, Golly F, Dreyfus H, Freysz L, Massarelli R. Effect of CDPcholine on hypocapnic neurons in culture. J Neurochem 1986; 47: 223-31.
41. Paxinos G, Franklin KBJ. The mouse brain in stereotaxic coordinates. New York, Academic Press; 2001.
42. Reyland ME. Protein kinase C isoforms: Multi-functional regulators of cell life and death. Front Biosci 2009; 14: 2386-99.
43. Singh V, Voss EV, Benardais K, Stangel M. Effects of 2-chlorodeoxyadenosine (Cladribine) on primary rat microglia. J Neuroimmune Pharmacol 2012; 7: 939-50.
44. Skripuletz T, Gudi V, Hackstette D, Stangel M. De-and remyelination in the CNS white and grey matter induced by cuprizone: the old, the new, and the unexpected. Histol Histopathol 2011; 26: 1585-97.
45. Skripuletz T, Hackstette D, Bauer K, Gudi V, Pul R, Voss E, et al. Astrocytes regulate myelin clearance through recruitment of microglia during cuprizone-induced demyelination. Brain 2013; 136: 147-67.
46. Skripuletz T, Lindner M, Kotsiari A, Garde N, Fokuhl J, Linsmeier F, et al. Cortical demyelination is prominent in the murine cuprizone model and is strain-dependent. Am J Pathol 2008; 172: 1053-61.
47. Skripuletz T, Miller E, Moharregh-Khiabani D, Blank A, Pul R, Gudi V, et al. Beneficial effects of minocycline on cuprizone induced cortical demyelination. Neurochem Res 2010; 35: 1422-33.
48. Smith T, Groom A, Zhu B, Turski L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 2000; 6: 62-66.
49. Tselis A, Khan OA, Lisak RP. Approaches to neuroprotective strategies in multiple sclerosis. Expert Opin Pharmacother 2010; 11: 2869-2878.
50. Weiss GB. Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. Life Sci 1995; 56: 637-660